Physician profile
Muhammad Shafi
NPI 1407298029
$5,428.18
in general payments reported to CMS, 2019-2025
28 companies · $1,566 in 2025
The $1,566 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.01 · 2021: $49.12 · 2022: $674 · 2023: $1,161 · 2024: $1,910 · 2025: $1,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,637.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,008.25 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $631.95 | 2022-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $587.32 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $387.10 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $306.87 | 2019-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $237.67 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.15 | 2023-2025 | Glassia, Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.86 | 2022-2023 | Ofev |
| Grifols USA, LLC | $215.67 | 2023-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $178.88 | 2022-2025 | Uptravi, Opsumit |
| United Therapeutics Corporation | $174.19 | 2022-2024 | Tyvaso |
| Mylan Specialty L.P. | $169.14 | 2021-2024 | Yupelri |
| Avadel Cns Pharmaceuticals, LLC | $154.24 | 2024-2025 | Lumryz |
| Jazz Pharmaceuticals INC. | $131.60 | 2023-2025 | |
| Amgen INC. | $131.60 | 2022-2025 | Tezspire |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $116.55 | 2023-2025 | Sunosi |
| Electromed, INC. | $93.32 | 2023-2024 | Smartvest |
| Inogen, INC. | $89.81 | 2023-2024 | Inogen At Home Stationary Concentrator |
| Baxter Healthcare | $70.38 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $49.60 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $49.06 | 2019-2024 | Xolair |
| Harmony Biosciences LLC | $40.12 | 2024 | |
| Philips North America LLC | $38.47 | 2024 | (Ak6) Vest Therapy |
| Melinta Therapeutics, LLC | $38.24 | 2023 | Vabomere |
| Csl Behring | $34.80 | 2024 | Kcentra |
| Viatris Specialty LLC | $28.73 | 2025 | Yupelri |
| Pfizer INC. | $19.12 | 2023 | |
| Lilly USA, LLC | $13.49 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Shafi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.